uploads/2018/03/Ophthalmology.png

How Novartis’s Ophthalmology Business Performed in 2017

By

Updated

Ophthalmology Business revenue trends

In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.4 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.

Article continues below advertisement

Lucentis revenue trends

In 4Q17, Novartis’s (NVS) Lucentis generated revenues of $485 million, which is ~7% growth on a YoY basis and 1% growth quarter-over-quarter. In fiscal 2017, Lucentis generated revenues of $1.9 billion compared to $1.8 billion in 2016, which reflected ~3% growth on a YoY basis.

The growth in sales volume across most markets primarily led to the revenue growth of Lucentis. Roche (RHHBY) commercializes Lucentis in the US market, while Novartis commercializes it outside the US market. In the marketplace, Lucentis’s competitors include Regeneron Pharmaceuticals’ (REGN) Eylea.

Travoprost Group’s revenue trends

In 4Q17, Travoprost generated revenues of $150 million, which is a ~7% decline on a YoY basis and 1% growth quarter-over-quarter. In fiscal 2017, Travoprost generated revenues of $589 million compared to $619 in 2016, which is a ~5% decline on a YoY basis.

The loss of market exclusivity in the European markets primarily led to the decline of Travoprost revenues. The Travoprost Group of drugs include Travatan, Travatan Z, and DuoTrav. In the marketplace, Travoprost’s peers include Allergan’s (AGN) Lumigan and Pfizer’s (PFE) Xalatan.

Article continues below advertisement

Systane Group’s revenue trends

In 4Q17, Systane Group generated revenues of $108 million, which is ~8% growth on a YoY basis and 8% growth quarter-over-quarter. In 2017, Systane Group reported revenues of $400 million compared to $377 million in 2016, which is ~6% growth on a YoY basis. The growth in sales of Systane in Europe and US markets primarily led to the revenue growth. Systane Ultra, Systane Balance, and Systane Hydration constitute the Systane Group portfolio.

Topical Olopatadine Group

In 4Q17, the Olopatadine Group generated revenues of $59 million, which is ~7% YoY growth and 20% quarter-over-quarter growth In fiscal 2017, Olopatadine generated revenues of $284 million compared to $335 million in 2016, which is a ~15% YoY decline.

Patanol, Pataday, and Pazeo constitute the Olopatadine Group of drugs. The Olopatadine revenues witnessed growth despite the loss of market exclusivity of Pataday in the US market.

Advertisement

More From Market Realist